Valpione, SaraMundra, Piyushkumar AGalvani, ElenaCampana, Luca G; orcid: 0000-0002-8466-8459Lorigan, Paul; orcid: 0000-0002-8875-2164De Rosa, Francesco; orcid: 0000-0003-0511-1298Gupta, AvinashWeightman, JohnMills, SarahDhomen, NathalieMarais, Richard; orcid: 0000-0001-7484-4183; email: richard.marais@cruk.manchester.ac.uk2021-08-042021-08-042021-07-02Nature communications, volume 12, issue 1, page 4098http://hdl.handle.net/10034/625474From Europe PMC via Jisc Publications RouterHistory: ppub 2021-07-01, epub 2021-07-02Publication status: PublishedFunder: Wellcome Trust; Grant(s): 100282/Z/12/ZFunder: Cancer Research UK; Grant(s): A22902, A27412Tumor infiltration by T cells is paramount for effective anti-cancer immune responses. We hypothesized that the T cell receptor (TCR) repertoire of tumor infiltrating T lymphocytes could therefore be indicative of the functional state of these cells and determine disease course at different stages in cancer progression. Here we show that the diversity of the TCR of tumor infiltrating T cell at baseline is prognostic in various cancers, whereas the TCR clonality of T cell infiltrating metastatic melanoma pre-treatment is predictive for activity and efficacy of PD1 blockade immunotherapy.Licence for this article: cc byT-LymphocytesLymphocytes, Tumor-InfiltratingHumansMelanomaSkin NeoplasmsReceptors, Antigen, T-CellBiopsyPrognosisImmunotherapySurvival RateCohort StudiesAdultAgedAged, 80 and overMiddle AgedFemaleMaleBiomarkers, Tumorarticle2021-08-04